These findings position IL-12 and IL-21 as promising armoring candidates to overcome exhaustion and enhance durability, while future approaches targeting metabolic fitness and resistance to tumor-derived immunosuppressive factors could further optimize CAR-iNKT efficacy across diverse malignancies. Here, IL21 is linked to neoplasm.